ReviewCureus2025
A Comprehensive Review of Food and Drug Administration (FDA)-Cleared Virtual Reality Technologies in Radiology.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Virtual reality (VR) is emerging as a clinically relevant tool in diagnostic radiology, offering immersive environments for image interpretation, medical education, and preoperative planning. Despite the field's continued reliance on two-dimensional (2D) monitors to assess inherently three-dimensional (3D) imaging data, immersive technologies remain underutilized in clinical workflows. As of 2024, the U.S. Food and Drug Administration (FDA) has cleared 69 devices categorized under virtual and augmented reality. This review focuses on the seven VR systems with direct applications in radiology: Ceevra Reveal 3+ (Ceevra, Inc., San Francisco, CA, USA), VSI HoloMedicine (apoQlar medical GmbH, Hamburg, Germany), Dextroscope (Volume Interactions Pte Ltd, Singapore), Dextrobeam (Volume Interactions), V3D-Colon (Viatronix, Inc., Stony Brook, NY, USA), V3D-Explorer (Viatronix), and V3D-Vascular (Viatronix). These platforms enable users to visualize, manipulate, and interpret radiological data in fully immersive 3D space, enhancing diagnostic precision, procedural planning, and interdisciplinary collaboration. Drawing on regulatory documentation and peer-reviewed evaluations, this article assesses the clinical functions, implementation challenges, and future potential of these technologies. As immersive tools gain regulatory momentum and technical refinement, VR is positioned to expand radiology's diagnostic capabilities and reshape its educational and clinical landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.